Lipocine announces license and supply agreement for tlando® in brazil

Salt lake city , may 6, 2025 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license and supply agreement with achÉ laboratÓrios farmacÊuitcos s.a (achÉ) granting exclusive rights to market tlando® in brazil. the market for prescription testosterone products in brazil is substantial and rapidly growing with compound annual growth rate (cagr) of 34% from 2019 to 2023 and no oral testosterone therapy registered in brazil.
LPCN Ratings Summary
LPCN Quant Ranking